Repligen Corp
(NAS:RGEN)
$
168.3
-3.48 (-2.03%)
Market Cap: 9.40 Bil
Enterprise Value: 9.54 Bil
PE Ratio: 673.20
PB Ratio: 4.77
GF Score: 93/100 Repligen Corp at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 26, 2021 / 05:00PM GMT
Release Date Price:
$212.39
(+2.57%)
Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst
Okay. Great. Welcome, everyone. I'm Puneet Souda, SVB Leerink tools and diagnostic analyst here. And it's a pleasure to be hosting Repligen management team. Joining us from Repligen is Tony Hunt, CEO; and Jon Snodgres, CFO. Hey guys, welcome. Glad to have you here.
Anthony J. Hunt
Repligen Corporation - CEO, President & Director
Puneet, good to see you.
Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst
Great. So just before we get started, I mean, to me, look, Repligen is a high-growth company in the bioprocessing space that is benefiting COVID vaccine ramp and is increasingly seeing growth from high-growth markets of cell and gene therapy. So obviously, a lot to cover here. Please send me questions through the chat if you have any or through e-mail, and we'll cover them during the session.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot